Hospital Carlos III-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2001

  1. Intensification of antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 17, Núm. 6, pp. 499-506

  2. Management of hepatitis C in HIV-infected persons

    Antiviral Research, Vol. 52, Núm. 2, pp. 189-198

  3. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens [3]

    Journal of Acquired Immune Deficiency Syndromes

2000

  1. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

    AIDS, Vol. 14, Núm. 4, pp. 383-386

  2. Intensificación del tratamiento antirretrovírico

    Revista Clinica Espanola, Vol. 200, Núm. 2, pp. 84-87

  3. Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 14, Núm. 15, pp. 2409-2410

  4. Second Spanish Consensus on the Use of Drug Resistance Testing in Clinical Practice (Madrid, March 2000)

    AIDS Reviews

  5. Terapia antirretrovírica de rescate

    Revista Clinica Espanola, Vol. 200, Núm. 2, pp. 88-94

1999

  1. Diabetes mellitus associated with protease inhibitor use

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 18, Núm. 9, pp. 675-677

  2. Higher antiviral activity of antiretroviral regimens including protease inhibitors [5]

    AIDS

  3. Introduction of HIV drug-resistance testing in clinical practice

    AIDS, Vol. 13, Núm. 9, pp. 1007-1014

  4. Management of chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 13, Núm. 5, pp. 539-546

  5. Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 18, Núm. 6, pp. 448-449

  6. What dual protease inhibitor combination for salvage therapies? [8]

    AIDS

1998

  1. Opportunistic infections shortly after beginning highly active antiretroviral therapy

    Antiviral Therapy, Vol. 3, Núm. 4, pp. 229-231